Subsequent Events

In October 2014, MorphoSys triggered the acquisition of LanthioPharma’s lanthipeptide technology for drug development by exercising an option within an existing collaboration and option agreement between the two companies from November 2012.

Shortly after the end of the third quarter 2014, MorphoSys received a milestone payment from its partner Janssen Biotech for the start of a phase 3 clinical trial with guselkumab.

Both events will impact the financial statements in Q4 of 2014.

No additional events occurred that require reporting.